R Squared Ltd Cuts Stake in IQVIA Holdings Inc. $IQV

R Squared Ltd lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 26.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,940 shares of the medical research company’s stock after selling 1,070 shares during the quarter. R Squared Ltd’s holdings in IQVIA were worth $463,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd grew its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA during the 1st quarter valued at approximately $33,000. Trust Co. of Toledo NA OH purchased a new position in IQVIA during the 2nd quarter valued at approximately $39,000. Finally, J.Safra Asset Management Corp grew its holdings in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $220.64 on Friday. The stock’s fifty day moving average is $194.47 and its 200 day moving average is $171.27. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $225.91. The firm has a market capitalization of $37.51 billion, a PE ratio of 31.93, a PEG ratio of 2.42 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the firm posted $2.64 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Robert W. Baird raised their price target on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.